Skip to main content

Voiding Dysfunction

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Handok
HandokKorea - Seoul
1 program
1
alfuzosin hydrochloride XL 10mgPhase 21 trial
Active Trials
NCT00679315Completed190Est. Dec 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Handokalfuzosin hydrochloride XL 10mg

Clinical Trials (1)

Total enrollment: 190 patients across 1 trials

NCT00679315Handokalfuzosin hydrochloride XL 10mg

Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female

Start: Jun 2008Est. completion: Dec 2009190 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.